CN115697308A - 包含结晶形式的rabeximod的口服制剂 - Google Patents

包含结晶形式的rabeximod的口服制剂 Download PDF

Info

Publication number
CN115697308A
CN115697308A CN202180042114.0A CN202180042114A CN115697308A CN 115697308 A CN115697308 A CN 115697308A CN 202180042114 A CN202180042114 A CN 202180042114A CN 115697308 A CN115697308 A CN 115697308A
Authority
CN
China
Prior art keywords
rabeximod
composition
rheumatoid arthritis
pharmaceutically acceptable
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180042114.0A
Other languages
English (en)
Chinese (zh)
Inventor
U·布乔科伦德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN115697308A publication Critical patent/CN115697308A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
CN202180042114.0A 2020-06-10 2021-06-10 包含结晶形式的rabeximod的口服制剂 Pending CN115697308A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP20179277 2020-06-10
EP20179279.3 2020-06-10
EP20179239 2020-06-10
EP20179239.7 2020-06-10
EP20179279 2020-06-10
EP20179277.7 2020-06-10
EP20180706.2 2020-06-18
EP20180706 2020-06-18
PCT/EP2021/065705 WO2021250204A1 (en) 2020-06-10 2021-06-10 Oral formulation comprising a crystalline form of rabeximod

Publications (1)

Publication Number Publication Date
CN115697308A true CN115697308A (zh) 2023-02-03

Family

ID=76305939

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202180042114.0A Pending CN115697308A (zh) 2020-06-10 2021-06-10 包含结晶形式的rabeximod的口服制剂
CN202510521204.8A Pending CN120383602A (zh) 2020-06-10 2021-06-10 用于制备结晶形式的rabeximod的方法
CN202180041778.5A Pending CN115698010A (zh) 2020-06-10 2021-06-10 用于制备结晶形式的rabeximod的方法
CN202180042179.5A Pending CN115768431A (zh) 2020-06-10 2021-06-10 治疗类风湿性关节炎中的rabeximod

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202510521204.8A Pending CN120383602A (zh) 2020-06-10 2021-06-10 用于制备结晶形式的rabeximod的方法
CN202180041778.5A Pending CN115698010A (zh) 2020-06-10 2021-06-10 用于制备结晶形式的rabeximod的方法
CN202180042179.5A Pending CN115768431A (zh) 2020-06-10 2021-06-10 治疗类风湿性关节炎中的rabeximod

Country Status (8)

Country Link
US (3) US12594274B2 (enExample)
EP (3) EP4164616A1 (enExample)
JP (3) JP2023529001A (enExample)
KR (3) KR20230022882A (enExample)
CN (4) CN115697308A (enExample)
AU (3) AU2021290174A1 (enExample)
CA (3) CA3181637A1 (enExample)
WO (3) WO2021250199A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023529001A (ja) 2020-06-10 2023-07-06 シクソン エービー 結晶形のラベキシモドを含む経口製剤
US11643415B1 (en) * 2021-12-09 2023-05-09 Cyxone Ab Rabeximod compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288296A1 (en) * 2004-06-17 2005-12-29 Jan Bergman Alkyl substituted indoloquinoxalines

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8600260D0 (sv) 1986-01-21 1986-01-21 Lundblad Leif Substituerade indolokinoxaliner
SE504289C2 (sv) * 1994-06-23 1996-12-23 Leif J I Lundblad Användning av vissa indolo-2,3b-kinoxaliner för framställning av ett läkemedel för inhibering av enzymet HIV-integras
JPH08165278A (ja) 1994-12-14 1996-06-25 Kawaken Fine Chem Co Ltd １−置換トリプタミン化合物の製造方法
SE504862C2 (sv) 1994-12-27 1997-05-20 Leif J I Lundblad Användning av vissa indolo-§2,3b¤-kinoxaliner för framställning av ett läkemedel för skydd av DNA i initieringsfasen och/eller promotionsfasen av karcinogenes och för förhindrande av oxidativ stress i patienter med sjukdomar relaterade till fria radikaler
DE19516804A1 (de) * 1995-05-08 1996-11-14 Hoechst Ag Isoindolinpigmente auf Basis von Aminochinoxalindionen
SE516067C2 (sv) 2000-02-18 2001-11-12 Lundblad Leif J I Användning av en förening för framställning av ett läkemedel
US6333327B2 (en) 2000-02-18 2001-12-25 Leif J. I. Lundblad Method for the treatment of Multiple Sclerosis
TW200410921A (en) * 2002-11-25 2004-07-01 Hoffmann La Roche Mandelic acid derivatives
ATE382623T1 (de) * 2004-06-09 2008-01-15 Hoffmann La Roche Octahydropyrrolo(3,4-c)pyrrolderivate und deren verwendung als antivirale mitteln
CN101558038B (zh) * 2006-11-30 2013-05-01 国立大学法人东京工业大学 姜黄素衍生物
CN102115457B (zh) 2011-03-05 2012-11-21 太原理工大学 一种n-乙基咔唑的制备方法
WO2013182905A2 (en) * 2012-06-05 2013-12-12 Jonas Axelsson Mechanism, diagnostic, and treatments for complications of renal failure
WO2014140321A1 (en) 2013-03-15 2014-09-18 Vironova Ab Antiviral indolo[2,3-b]quinoxaline
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
CN105061432B (zh) 2015-07-16 2017-09-29 河北大学 6H‑吲哚[2,3‑b]喹喔啉衍生物、药物组合物及其制备和应用
TWI721483B (zh) * 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
WO2021250196A1 (en) 2020-06-10 2021-12-16 Cyxone Ab New use of rabeximod
JP2023529001A (ja) 2020-06-10 2023-07-06 シクソン エービー 結晶形のラベキシモドを含む経口製剤
US11643415B1 (en) * 2021-12-09 2023-05-09 Cyxone Ab Rabeximod compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288296A1 (en) * 2004-06-17 2005-12-29 Jan Bergman Alkyl substituted indoloquinoxalines

Also Published As

Publication number Publication date
CN115698010A (zh) 2023-02-03
KR20230022880A (ko) 2023-02-16
JP2023529001A (ja) 2023-07-06
CA3181646A1 (en) 2021-12-16
KR20230022881A (ko) 2023-02-16
EP4164650A1 (en) 2023-04-19
AU2021290173A1 (en) 2023-02-09
EP4165043A1 (en) 2023-04-19
US20220133717A1 (en) 2022-05-05
JP2023533662A (ja) 2023-08-04
AU2021290174A1 (en) 2023-02-09
CN115768431A (zh) 2023-03-07
CA3181629A1 (en) 2021-12-16
US12673056B2 (en) 2026-07-07
US20230227455A1 (en) 2023-07-20
CA3181637A1 (en) 2021-12-16
WO2021250197A1 (en) 2021-12-16
WO2021250204A1 (en) 2021-12-16
JP2023529877A (ja) 2023-07-12
EP4164616A1 (en) 2023-04-19
US12594274B2 (en) 2026-04-07
KR20230022882A (ko) 2023-02-16
US20230227456A1 (en) 2023-07-20
CN120383602A (zh) 2025-07-29
AU2021289006A1 (en) 2023-02-09
WO2021250199A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
JP2023112149A (ja) パルボシクリブの固形剤形
EP1049467B1 (en) Celecoxib compositions
CN1114879A (zh) 阿齐霉素的给药方法
JP2020063292A (ja) ランタン化合物を含むカプセル製剤及び粉末製剤
WO2013044356A1 (en) Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d
EP3909567A1 (en) Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US20250009722A1 (en) Treatment of migraine
CN101022789A (zh) 一种药物组合物
CN105073101B (zh) 具有高含量非索非那定的固体单元及其制备方法
CN106560179B (zh) 盐酸卡利拉嗪药物组合物及其制备方法
WO2021250204A1 (en) Oral formulation comprising a crystalline form of rabeximod
EP3052130B1 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
JP3545300B2 (ja) 固体の経口用イフォスファミド医薬組成物およびその製造法
JP2025081700A (ja) 改変剤形を調製する方法および関連する構成成分
CN103687592A (zh) 包含非索非那定的药物组合物
CN102740831B (zh) 包含纯奥利司他的预混合物的具有抗肥胖活性的药物组合物和制备方法
EP2809306A2 (en) New pharmaceutical compositions of flurbiprofen and glucosamin
WO2021099481A1 (en) Solid composition containing rufinamide
WO2025196560A1 (en) An orodispersible tablet of pregabalin and its process of preparation
KR20200113116A (ko) 데페라시록스를 포함하는 필름코팅정제
CZ20002769A3 (cs) Kompozice obsahující celecoxib

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230203